Member Info for PM2022

It's good for building knowledge. Most AIM companies I have no idea what is going on.

Downside is that people think they can predict when the next news is due which is why Suzy should send a surprise RNS at times and 201 should be done when most of these traders are locked out so they jump in on a premium.

when complete.

reference 11 min into the presentation. TRX has a plan to get the funding and Val will be able to sign the sublicence. VAL have been working on costs and help to plan for when funding has been completed.

We are at a stronger stage than we have been over the last two years even when we were 65p. The deal will land when it lands. Triple Negative drug worth more than our market cap and a second and possibly a third due soon. Numerous other drugs and a lab on the way.

I still believe we should be 40p-50p before the deal at the moment. I am confident we will reverse.

from

I stick with Adam on this one. He knows his stuff. Worst case he comes on the VAL board if he wishes if they make any more bad moves. I think he would get 100% support for real holders.

Great post by Adam:

RE: The Naivety of the BOD is Breathtaking Today 12:41
1. Speculation. See C4X/Sanofi. Il-17 inhibitor partnered for a 400ME package, at a stage barely beyond where we are at with KCTNBC. There's lots of others, too - look up RedX and AZ, and RedX and Jazz. All partnered with compounds months only ahead of ours.
2. Speculation. Name me three “significantly lower risk M&A” offerings, with “quicker returns”, and why.
3. Google Ken and Patrick. There’s a lot of previous M&A (including listed outfits) activity. I am not in any way defending their poorly-executed one-sided “deal” here, but you are materially incorrect with that statement about Ken.
4. The one point I agree with. Deal as above.
5. This is the right approach. You’d raise at 8p for an over-priced “Client list”, which you simply do not need in this sphere. I know this because I own one of a small number of GLP -certified, MHRA-accredited labs. Started from scratch. Capacity met within 4 months. Over-subscribed now for 10 years straight. Initial scaling will demonstrate to a potential II (should expansion be warranted – which I think it will), a growth potential for investment. It’s a no-brainer for me.
6. You have no idea how successful this will be in 2023. I have an idea, because I’ve done it. I know what they’re going to offer, and I know that they will, likely within the year, already be under-capacity. Believe me, is you offer a reliable niche service, Clients will literally “fall from the sky”.
7. If you’d raise at the lowest SP with a 8-10 month runway and potential inflection points, fair enough. I wouldn’t. I’d get the lab spinning 1Q 2023, which they are doing.
8. This is for the BOD to answer, but they may be in a closed period still, with 201/TX.

So, all in all, a good point in there Porky, which we agree on.

No I mean that may have been the expectation at the time. Due to patent work and less data probably not one they could get at the time.

Don't worry about Porky. We know he is 100% negative the last six months always has excuses. He promised he would buy time and again once staff were added. He has no money to buy and it is clear he holds a grudge against the company.

Whatever Porky we know your agenda. You hold a personal grudge against VAL. One only needs to check your posting history.

I guess you blame Val because they picked TRX instead of AZ and it made you sell and buy DDDD and now you lost all your money.

Not anytime soon when they should have more than enough cash until summer/autumn next year.

The smart money is on a buy and hold at these prices. They want those options for all the staff 30/40p.

Provide us with an alternative argument ? Lots of people know what price I buy at and you are at not one of those people.

This is my analysis but it is just an opinion based on logic so make up your minds.

We would likely have sufficient for about 9-12 months but the extra 300k perhaps takes us into the summer. Remember they save money as well.

Remember the board Suzy/Kevin has about 500/600 k options. That is a sufficient amount for them from 10p so If I am correct it probably works at about a six figure bonus. They want this within the timeframe. Work it out yourself. The plan is simple.

1)The rented lab comes in and they generate revenue very fast and by the summer they could have more than enough revenue coming in to give extra time if they need to raise at all.
2)The better plan could be to give stock to an institutional investor who buys into the plan and holds for a few years like they do possibly with a locked in period. This keeps the free float as it is and it's not really a dilution. They sell when the market cap is 50-100 million or more.
3) They dilute after Feb when the next big news is due at 20-30p range. This is a tiny dilution maybe 5-10% for an extra million or two. Overtime market cap increases by ten fold so it would not make a difference at the price. Ideally they would look to avoid this option if they are protecting options but it would not make a big difference.

They did budget for more evaluations last year but did not take them on so they saved a few 100k on that so far. Basically in my view if one can hold for a few months or more then it is likely to be the best risk to reward you will ever come across. I say this because the downside is very little and they take the evaluations on for about 100k or less and if successful it is valued at about 10 million and grows very fast with to options to get a deal or sell. Remember the lab will enable them to push it through faster.

By Feb we could have two in SPV which instantly values us above about 30p. 201/301 gets added as a freebie but when it is done the price moves up very fast but even without that we should get some large investors coming in and it should hit a 50 million market cap soon.

From 11p it is easy to multibag but just my opinion.

Excellent. Maybe no more placings. Not much downside as lab overheads covered. Fast evaluations which increase in value so from zero or 100k to 10 million in a matter of a few months. Not sure if she said they don't have to pay the 100k fees but I think that was what was said.

Barcelona evaluation sounds good and could add another 10 million to our market cap soon. All good and we are cheap at our current market cap.

Add in 201 when it happens. Today showed less downside and more potential overtime.

Keep calm. As long as we have something to look forward to then recovery can happen soon but not in many years given where we are.

I believe 201 will come good and the strategy will kick off.. Value is on offer here so expect a rebound. Patience is the key here.

2PM today Valirx presentation you should all get some decent hints imo. Hopefully 201 soon.

https://www.valirx.com/news/valirx-host-live-qa-shareholder-webinar

RNS 30 June
Dr Ken Sorensen, Chairman of TheoremRx stated: "We have appreciated the work carried out so far, and we remain confident of being able to complete our financing round. VAL201 is an important part of our pipeline of new projects."

RNS 23rd March. We have made positive progress towards securing the desired funding to cover the breadth of our pipeline, and we remain highly confident of success."

I think the situation is very simple but has been made complicated by Valirx even though it is information in previous RNSs. It is clear that TRX is building a portfolio of drugs. Negotiations with other companies take time. I feel people think the deal will not get done due to delays and problems with financing. I believe it is because TRX are building a portfolio of drugs and you would only do this if financing has been agreed in principle otherwise it would be a waste of time. This information is already in previous RNS but people have not taken note.

The uncertainty can easily be removed here by Dr Suzy.

If a deal gets done here as expected I see the strategy progressing very well and I see us heading to 50p plus.

She can't but last year the SP went from 20s to 50s after her presentation based on anticipation for 201.

It's all about understanding the potential on offer and what can happen and when and that gives an opportunity for buyers to come in.

At 12p I think many will be watching closely as this has a real potential to 10 bag in the next 1-2 years.

Suzy will be presenting tomorrow. You could potentially find out some details/hints regarding 201 and this could be the reason for the rise here.

Get tuned in tomorrow :

We are pleased to invite shareholders to join us for a Live Webinar Q&A on 13 December 2022 at 2pm where members of the Board will be available to answer questions. The webinar will be hosted via the BRR Media platform with registration details posted on our website closer to the event.

I would have to disagree. PYC still needs revenue to cover costs. If VAL 201 gets to market it might take about 5-6 years.

Once finance has been confirmed naturally as a phase 2 drug some of that revenue will be priced here but not all. So I would expect maybe it will add about 30-40 million to the market cap here based on some potential. That will not happen to PYC until the drug gets to market imo.

If you are investing in PYC for future revenue then you need to consider multiple dilutions over the next 5-6 years. With VAL it is different as in the next 1-2 years we will have preclinical drugs to sell for deals worth 100s million. We have other drugs 301 or 401 and we don't pay for the trails for 201. Also the rented lab may cover our costs.

Anyway it will be good for both companies but for PYC the 6% value will not be realised until it gets to market imo. Just the way I see it works in AIM when one company owns a stake. Personally PYC with such a low market cap I see it as risky because they can only raise a certain amount and therefore it can go bust if it cannot raise enough cash. Just my opinion with a market cap of just 2 million. To raise 1 million it is a 50% dilution therefore you can do the maths not great imo. VAL is different.

PYC gets as good as a bag of peanuts if the deal is done at the moment whereas VAL will be the huge riser. 6% of the upfront payment not 6 million. The 6 million is if val makes 100 million revenue years later capped at that level as far I remember but check it yourself in the RNS.

How can PYC get more than VAL when they only get 6% of what we get and that people falsely claim to be 6 million as an immediate payment.

Could it be the VAL 201 deal here. It's due finally been time. PYC gets 6% of the money VALIRX gets but VAL has so many other drugs. PYC helps out VAL and both will gain but I guess VAL will be a huge riser if the deal gets done. GL all.

Last few at 12p. FInal call who wants it.

At this price Suzy just needs to show a bit of value in the presentation and that should be easy at this price. Lots of news due in the next few weeks.